The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic. Although the efficacy of these vaccines is beyond doubt, safety still remains a concern. Liver injury, such as autoimmune hepatitis (AIH), has been reported after COVID-19 vaccination. The aim of this prospective study is to investigate the spectrum and profile of liver injury after COVID-19 vaccination in Asia-Pacific region and to explore the potential risk factors for the development of liver injury.
Study Type
OBSERVATIONAL
Enrollment
379
Vaccination for COVI9-19
Humanity & Health Medical Group Limited
Hong Kong, Hong Kong
Nihon University School of Medicine
Tokyo, Japan
Tokyo University
Tokyo, Japan
Number of subjects with liver injury after COVID-19 vaccination
The COVID-19 vaccine-related liver injury (such as elevated liver enzymes, total bilirubin, etc.) was recorded and its spectrum and profile were evaluated.
Time frame: Within 24 weeks after COVID-19 vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.